New Delhi, June 22, 2016
– The IPM grew at 10% in May 2016
– The IPM was valued at Rs.106, 134 crores and the retail sector was valued at Rs.89,071 crores as of MAT May 2016
– 3.4% IPM affected due to the recent ban imposed by the GOI on 344 drugs; acute therapies form 81% of the total banned portfolio
– In the Banned Portfolio analysis, Respiratory constitutes 43% of the overall value; however all other therapeutic areas see a massive dip since February 2016
– In terms of companies, Top 10 companies affected by the ban contribute to 62% of the overall value of the banned portfolio
– Pfizer though contributing highest to banned portfolio reflects positive growth since last three months
IMS Health Market Reflection Report – May 2016
Corporate Comm India (CCI Newswire)
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…